Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Acta Gastroenterol Latinoam ; 29(2): 47-50, 1999.
Artigo em Espanhol | MEDLINE | ID: mdl-10491714

RESUMO

Helicobacter pylori (HP) eradication reduces dramatically the peptic ulcer relapse rate, but information regarding recurrence of peptic ulcer bleeding after eradication is still scanty. Available data show rebleeding rates of 0-3% per year in successfully eradication patients, compared with figures between 12 and 33% among the non eradicated ones. The aim of this study was to determine the rebleeding rate among successfully eradicated patients with a prior history of rebleeding peptic ulcer. 42 patients (34 male, mean age 49, range 18-74) hospitalised for Hp positive bleeding peptic ulcer undergoing conservative treatment, were given as soon as oral route was re-established, a one-week eradication treatment, followed by the same proton pump inhibitor for three or five weeks for duodenal and gastric ulcer healing respectively. No maintenance antiulcer therapy was indicated. Patients were advised not to take nonsteroideal anti-inflammatory drug. Ulcer healing and Hp eradication was confirmed in all 42 patients by means of endoscopy and biopsies for urease rapid test and histology four weeks after completion of the treatment. After this patients were invited to enter a long-term follow-up program with periodical visits. End point of the study was occurrence of rebleeding. Further endoscopies were planned when rebleeding or symptomatic relapse. Median follow-up time was 24.02 months, ranging from 3 up to 27 months. All patients were compliant with the follow-up visits. None of the patients presented with symptoms suggestive of ulcer relapse or upper gastrointestinal bleeding. Our data suggest, that Hp eradication can prevent bleeding relapses in patients with Hp positive bleeding peptic ulcers.


Assuntos
Antiulcerosos/uso terapêutico , Infecções por Helicobacter/complicações , Helicobacter pylori , Úlcera Péptica Hemorrágica/tratamento farmacológico , Adolescente , Adulto , Idoso , Quimioterapia Combinada , Úlcera Duodenal/tratamento farmacológico , Úlcera Duodenal/prevenção & controle , Feminino , Seguimentos , Infecções por Helicobacter/tratamento farmacológico , Humanos , Masculino , Pessoa de Meia-Idade , Úlcera Péptica Hemorrágica/prevenção & controle , Recidiva , Resultado do Tratamento
2.
Acta gastroenterol. latinoam ; 29(2): 47-50, 1999.
Artigo em Espanhol | LILACS | ID: lil-241187

RESUMO

El objetivo de este trabajo fue determinar la tasa de resangrado en pacientes con historia previa de ulcera péptica sangrante H.P. positiva. 42 pacientes hospitalizados por úlceras pépticas sangrante fueron sujetos a tratamiento convencional para el cese de sangrado. Se les efectuó luego taramiento de erradicación del H.P. con triple terapia a 7 días sin mantenimiento posterior. A 4 semanas en el caso de ulcera duodenal y a 6 semanas en casos de ulcera gástrica se comprobó por vía endoscópica e histológica la curación de la úlcera y la erradicación de la bacteria. Los 42 pacientes fueron incluidos en un estudio de seguimiento y al cumplirse 24,02 meses (rango 3-27 meses) no hubo recidiva de la hemorragia en ninguno de ellos. Estos datos sugieren que la erradicación de H.P. puede prevenir la recidiva de sangrado ulceroso en pacientes H.P. positivos.


Assuntos
Humanos , Masculino , Feminino , Adolescente , Idoso , Pessoa de Meia-Idade , Antiulcerosos/uso terapêutico , Infecções por Helicobacter/tratamento farmacológico , Helicobacter pylori/efeitos dos fármacos , Úlcera Péptica Hemorrágica/tratamento farmacológico , Quimioterapia Combinada , Úlcera Duodenal/tratamento farmacológico , Úlcera Duodenal/prevenção & controle , Seguimentos , Recidiva , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA